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Abstract. Malignant pleural mesothelioma is a global health 
issue. Arsenic trioxide (ATO) has been shown to suppress 
thymidylate synthase (TYMS) in lung adenocarcinoma and 
colorectal cancer, and induce apoptosis in acute promyelo-
cytic leukemia. With TYMS as a putative therapeutic target, 
the effect of ATO in mesothelioma was therefore studied. 
A panel of 5 mesothelioma cell lines was used to study the 
effect of ATO on cell viability, protein expression, mRNA 
expression and TYMS activity by MTT assay, western blot, 
qPCR and tritium-release assay, respectively. The knockdown 
of TYMS and E2F1 was performed with a specific siRNA. 
Phosphatidylserine externalization and mitochondrial 
membrane depolarization were measured by Annexin V and 
JC-1 staining respectively. The in vivo effect of ATO was 
studied using a nude mouse xenograft model. Application of 
ATO demonstrated anticancer effects in the cell line model 
with clinically achievable concentrations. Downregulation 
of TYMS protein (except H226 cells and 1.25 µM ATO in 
H2052 cells) and mRNA expression (H28 cells), pRB1 (H28 
cells) and E2F1 and TYMS activity (except H226 cells) were 
also evident. E2F1 knockdown decreased cell viability more 
significantly than TYMS knockdown. In general, thymidine 
kinase 1, ribonucleotide reductase M1, c-myc and skp2 were 
downregulated by ATO. p-c-Jun was downregulated in H28 
cells while upregulated in 211H cells. Phosphatidylserine 
externalization, mitochondrial membrane depolarization, 
downregulation of Bcl-2 and Bcl-xL, and upregulation of Bak 
and cleaved caspase-3 were observed. In the H226 xenograft 
model, the relative tumor growth was aborted, and E2F1 was 
downregulated while cleaved caspase-3 was elevated and 
localized to the nucleus in the ATO treatment group. ATO has 
potent antiproliferative and cytotoxic effects in mesothelioma 
in vitro and in vivo, partially mediated through E2F1 targeting 
(less effect through TYMS targeting). There is sound scientific 
evidence to support the clinical application of ATO in treat-
ment of mesothelioma.
Introduction
Malignant pleural mesothelioma (MPM) arises from exposure 
to asbestos fibers with a long latency period and has been a 
global health problem for the past few decades. Its peak inci-
dence is yet to be reached. Mortality and morbidity remain 
extremely high, and treatment is rarely curative. Surgery 
alone or in combination with radiotherapy and chemotherapy 
(1) remains the standard treatment for early-stage disease. 
Combination chemotherapy for advanced disease has modest 
survival benefit (2). Thymidylate synthase (TYMS) converts 
2'-deoxyuridine-monophosphate (dUMP) to deoxythymidine-
5'-monophosphate (dTMP) in DNA synthesis (3). Pemetrexed is 
an antifolate that mainly inhibits TYMS to abort DNA synthesis 
and cell division: overexpression of TYMS has resulted in 
pemetrexed resistance (4,5). Notably, TYMS is a key pharma-
cological target in MPM though its role is still controversial 
(6,7). Alternative treatment options are very limited, especially 
for patients with a poor response to previous chemotherapy.
Most anticancer drugs work through inhibition of cellular 
proliferation or reactivation of apoptosis. The mechanisms of 
apoptosis in mesothelioma are less well-known, although it is 
frequently impeded (8). Thus development of anticancer drugs 
with novel targets that can inhibit cell proliferation and induce 
apoptosis is urgently needed to improve the overall outcome 
for patients with mesothelioma.
Arsenic trioxide (As2O3 or ATO) is the active component 
of a traditional Chinese medicine called Pi Shuang. ATO has 
demonstrated significant clinical activity in acute promy-
elocytic leukemia (APL): an intravenous formulation was 
approved by the US Food and Drug Administration over a 
decade ago. Our institution has subsequently pioneered the 
development of an oral preparation of ATO for clinical use 
with a much better safety profile (9). Interestingly, ATO has 
recently been shown to decrease TYMS expression in lung 
adenocarcinoma (10) and colorectal cancer (11), suggesting a 
possible role as a TYMS inhibitor. Nonetheless, the therapeutic 
role and targets of ATO in mesothelioma are less well-known 
and only two publications are available: ATO induced apop-
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tosis through JNK and ERK (12) and repressed Hedgehog 
signal transduction pathway (13). Specifically the upstream 
transcription factor of TYMS, E2F1, which is responsible 
for controlling proliferation and apoptosis (14), has not been 
explored as a therapeutic target in mesothelioma. We therefore 
aimed to investigate the anticancer effect and target of ATO 
in mesothelioma in vitro and in vivo, and provide a scientific 
basis for the future clinical development of ATO as a treatment 
for MPM.
Materials and methods
Cell lines and reagents. A panel of five mesothelioma cell 
lines [NCI-H28 (sarcomatoid), MSTO-211H (biphasic), 
NCI-H226 (epithelioid), NCI-H2052 (sarcomatoid) and 
NCI-H2452 (epithelioid)] was purchased (American Type 
Culture Collection, Manassas, VA, USA). Cells were incu-
bated in RPMI-1640 medium (Gibco®, Life Technologies, 
Carlsbad, CA, USA) enriched with 10% fetal bovine serum 
(FBS) (Gibco) in a humidified atmosphere of 5% CO2 at 37˚C. 
ATO (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 
sodium hydroxide (1.65 M) with pH adjusted to 7.4 by 6 M 
hydrochloric acid.
Cell viability assay. Briefly, cells (5,000/well) were incubated 
with different concentrations of ATO. Cells incubated with 
medium only served as a negative control. Following incubation 
for 48 or 72 h, cells were stained with 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) for 2 h, followed 
by addition of DMSO after removal of all medium. Absorbance 
(595 nm) was measured using a microplate reader Fluo Star 
Optima (Bmg Labtec GmbH, Ortenberg, Germany (10).
Western blotting study of whole-cell lysate. Western blotting 
was performed as previously described (15). Specific primary 
antibodies [mouse monoclonal anti-human β-actin (Sigma-
Aldrich), anti-c-Myc, anti-E2F1, anti-p-c-Jun, anti-pRB1, 
anti-TYMS, anti-thymidine kinase 1, anti-ribonucleotide 
reductase M1, anti-skp2, anti-Bcl-2, anti-Bcl-xL, anti-Bak and 
anti-cleaved caspase-3 (Cell Signaling Technology, Danvers, 
MA, USA) antibodies] and corresponding horseradish peroxi-
dase (HRP)-conjugated secondary antibody (Cell Signaling 
Technology) were purchased. An enhanced chemilumines-
cence (ECL) kit (GE Healthcare) was used to detect protein 
expression. β-actin was selected as reference protein.
Quantification of TYMS mRNA. A standard TRIzol/chloro-
form method was used to extract total cellular RNA. Reverse 
transcription and quantitative polymerase chain reaction 
(qPCR) were performed using the PowerSYBR® Green Cells-
to-CT™ kit (Life Technologies) and standard protocol in 
StepOnePlus Real-Time PCR System (Applied Biosystems, 
CA, USA). The sequence of TYMS forward and reverse 
primers were TCAAGGGATCCACAAATGCT and TCTG 
TCGTCAGGGTTGGTTT, respectively. GAPDH served as 
internal control. Relative expression was calculated (10).
TYMS activity using tritium-release assay. Cells were incu-
bated for 2 h in fresh medium containing 3 µl [5-3H]-dUMP 
(American Radiolabeled Chemical, MO, USA) per well. The 
medium was collected, and mixed with charcoal and trichlo-
roacetic acid before centrifugation. One milliliter scintillation 
fluid was added to the supernatant and read using a scintilla-
tion counter (16). TYMS activity = total scintillation count of 
sample/total scintillation count of control.
TYMS and E2F1 siRNA knockdown. TYMS (sc-44978), 
E2F1 (sc-29297) or control (sc-37007) siRNA (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA) was allowed to 
transfect cells for 6 h using a transfection reagent (Santa Cruz 
Biotechnology) in RPMI-1640 medium, followed by replenish-
ment with new medium containing 1% FBS for 3 days (10). Cell 
viability, TYMS and E2F1 protein expression were measured.
Measurement of phosphatidylserine externalization. Cells 
were stained at room temperature for 20 min with phycoery-
thrin (PE)-conjugated Annexin V and 7-amino-actinomycin 
(AAD) (BD Phamingen, CA, USA) in binding buffer and incu-
bated in darkness. Cells were then analyzed by flow cytometry 
using FL-2 (575 nm) and FL-4 channel (675 nm) with Beckman 
FC500 (Beckman Coulter, Brea, CA, USA) (15).
Measurement of mitochondrial membrane potential. In short, 
cells were incubated for 15 min at 37˚C in 500 µl RPMI 
medium containing 5,5',6,6'-tetrachloro-1,1',3,3'tetraethylbenz
imidazolylcarbocyanine iodide (JC-1) (Sigma-Aldrich) in the 
dark. Cells were then analyzed using flow cytometry FL-1 
(525 nm) and FL-2 (575 nm) channel (Beckman FC500).
Tumor growth inhibition in vivo. The H226 xenograft model 
was created by subcutaneous injection of 107 cells in phos-
phate-buffered saline (PBS) into the upper back of 18 nude 
mice (female, 4-6-week-old, 10-14 g, BALB/cAnN-nu, Charles 
River Laboratories, Wilmington, MA, USA). Mice were 
randomized into 3 groups after tumor growth was established. 
PBS (served as control) or ATO (3.75 and 7.5 mg/kg) was 
administered daily intraperitoneally. Tumor dimension (using 
standard calipers) and body weight of mice were measured on 
alternate days and tumor volume calculated [volume = length 
x width x width)/2] (17). For humane reasons, mice were sacri-
ficed when tumor size reached 17 mm in diameter. Part of the 
tumor xenografts were collected and lysed for western blot-
ting. The remainder was fixed in paraffin block and cut into 
sections for immunohistochemical (IHC) staining according 
to standard procedures. The study protocol was approved by 
the institutional Animal Ethics Committee (approval reference 
no. CULATR 2510-11), and standard humane endpoints for 
animal research were applied.
Statistical analysis. Experiments were repeated at least 3 times 
and data analysed (mean ± standard deviation). The difference 
between groups was analyzed using Student's two-tailed t-test 
by Prism (GraphPad Software, La Jolla, CA, USA). A p-value 
<0.05 defined statistical significance (*p<0.05, **p<0.01, 
***p<0.001 in the figures).
Results
In vitro activity of ATO in mesothelioma. Treatment with ATO 
induced a dose- and time-dependent antiproliferative effect in 
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Figure 1. (A) Basal TYMS protein expression in different mesothelioma cell lines. H28 cells showed the highest expression level while 211H cells did not 
display any basal expression. Alternation of TYMS (B) protein and (C) mRNA (H28 cells) by incubation with ATO. ATO downregulated TYMS protein 
expression except H226 cells and at low concentration (1.25 µM ATO) in H2052 cells. (D) ATO induced a decrease in protein expression of (D) pRB1 in H28 
cells and (E) E2F1 in all cell lines in a dose-dependent manner. (F) TYMS activity of different mesothelioma cells after exposure to ATO for 48 h. TYMS 
activity was inhibited after incubation of ATO in H28, H2052 and H2452 cells while increased in H226 cells. Results were measured in triplicate experiments. 
A representative result of western blotting is displayed. Statistical significance (*p<0.05, **p<0.01, ***p<0.001) indicates comparison with control.
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all mesothelioma cell lines. The IC50 values in different cell 
lines were 4.7-7.8 µM (H28, 211H, H226, H2052 and H2452 
cells: 6.9±1.6, 6.6±1.1, 7.8±1.1, 4.7±2.1 and 5.6±2.6 µM 
respectively) and 1.7-7 µM (H28, 211H, H226, H2052 and 
H2452 cells: 2.1±0.7, 7.0±0.6, 6.6±1.0, 1.7±0.5 and 2.8±0.8 µM 
respectively) after 48- and 72-h treatment, respectively.
Effects of ATO on TYMS protein and mRNA expression, pRB1 
and E2F1 protein expression and TYMS activity. Basal TYMS 
protein expression is shown in Fig. 1A. H28 cells displayed 
the highest TYMS protein expression. The TYMS expression 
levels in H226, H2052 and H2452 cells were similar, but unde-
tectable in 211H cells. Following a 48-h incubation with ATO, 
TYMS protein expression was decreased in H28 and H2452 
cells, and increased in H226 cells in a dose-dependent manner. 
The TYMS protein expression was first increased (1.25 µM 
ATO), then decreased at higher concentrations of ATO in 
H2052 cells (Fig. 1B). TYMS mRNA expression was signifi-
cantly decreased in H28 cells (Fig. 1C), while basal TYMS 
mRNA expression was undetectable in other cells. Basal 
pRB1 was highly expressed and downregulated in H28 cells 
in a dose-dependent manner after ATO treatment (Fig. 1D), 
but undetectable in other cells. Upon ATO treatment, expres-
sion of E2F1 protein was decreased significantly in all cell 
lines (Fig. 1E). ATO inhibited TYMS activity in H28, H2052 
and H2452 cells, but increased TYMS activity in H226 cells 
(Fig. 1F).
Decreased cell viability after knockdown of TYMS and E2F1. 
H28, H226, H2052 and H2452 cells were used in TYMS 
silencing experiment, however, H2452 cells could not survive in 
1% FBS condition. TYMS siRNA reduced the relative TYMS 
protein expression to <10% that of the control siRNA and was 
associated with a 25% reduction in cell viability in H28 and 
H226 cells but unaltered viability in H2052 cells (Fig. 2A). 
E2F1 siRNA decreased the relative E2F1 protein expression to 
~35, 12, 19 and 26% that of the control siRNA and was associ-
ated with 57, 72, 37 and 45% reduction in cell viability in H28, 
211H, H226 and H2052 cells, respectively (Fig. 2B).
Alteration of E2F1 downstream targets by ATO. ATO decreased 
expression of thymidine kinase 1 (TK) in H28 cells, but 
upregulated TK expression initially at 1.25 µM and then 
downregulated with higher concentrations in H2052 cells. 
Figure 2. Effect of TYMS-targeted and E2F1-targeted siRNA on TYMS and E2F1 protein expression and cell viability in different cell lines. Since 211H cells 
did not express TYMS, and H2452 cells could not survive in 1% FBS condition, only H28, H226 and H2052 cells were used in TYMS knockdown experiment. 
(A) TYMS siRNA reduced the relative TYMS protein expression when compared with control siRNA arm and associated with different degrees of reduction in 
cell viability in H28 and H226 cells. TYMS knockdown had no effect on cell viability in H2052 cells. (B) H28, 211H, H226 and H2052 cells were used in E2F1 
knockdown experiment. E2F1 siRNA decreased the relative E2F1 protein expression when compared with control siRNA group and was associated with decrease 
in cell viability in all cell lines. Results were measured in triplicate experiments. A representative result of western blotting is shown. Statistical significance 
(*p<0.05, **p<0.01, ***p<0.001) indicates comparison with control.
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The expression of ribonucleotide reductase M1 (RRM1) 
was suppressed in H28, 211H and H2052 cells. ATO down-
regulated the expression of c-myc and skp2 in all cell lines. 
The expression of p-c-Jun was decreased in H28 cells while 
upregulated in 211H cells (Fig. 3).
Phosphatidylserine (PS) externalization and mitochondrial 
membrane depolarization induced by ATO. PS externaliza-
tion induced by ATO was observed in H2452 cells (Fig. 4A) 
although ATO enhanced mitochondrial membrane depolariza-
tion in all cell lines in a dose-dependent manner (Fig. 4B).
Figure 3. Alteration in expression of TK, RRM1, c-myc, skp2 and p-c-Jun in different cell lines upon ATO treatment. Basal expression of TK in 211H, H226 
and H2452 cells was undetectable. ATO downregulated the expression of TK (H28 and H2052 cells), RRM1 (H28, 211H and H2052 cells), c-myc and skp2. 
p-c-Jun expression was decreased in H28 cells and increased in 211H cells. A representative result of western blotting is shown. Statistical significance 
(*p<0.05, **p<0.01, ***p<0.001) indicates comparison with control.
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Alteration of apoptosis-related factors by ATO. The expres-
sion of anti-apoptotic factor Bcl-2 was downregulated in a 
dose-dependent manner with ATO treatment in all cell lines 
except H28 cells (Fig. 5A). The anti-apoptotic factor Bcl-xL 
was suppressed in H2052 cells (Fig. 5B). The expression of the 
downstream Bak in 211H, H226 and H2052 cells was upregu-
Figure 4. (A) Phosphatidylserine externalization was induced by ATO in a 
dose-dependent manner in H2452 cells and (B) mitochondrial membrane 
depolarization was observed in all cell lines in a a dose-dependent manner 
after incubation of ATO for 48 h. Statistical significance (*p<0.05, **p<0.01, 
***p<0.001) indicates comparison with control.
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Figure 5. Alteration in pro-apoptotic and anti-apoptotic factors in different 
ATO-treated mesothelioma cell lines. (A) Bcl-2 suppression was observed in 
all cell lines except H28 while (B) basal Bcl-xL was detected and repressed 
only in H2052 cells. (C) Bak was upregulated in 211H, H226 and H2052 
cells. (D) Cleaved caspase-3 was upregulated by ATO in a dose-dependent 
manner in all cell lines. Statistical significance (*p<0.05, **p<0.01, ***p<0.001) 
indicates comparison with control.
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lated when the concentration of ATO increased (Fig. 5C). 
Expression of cleaved caspase-3 (CC3) was increased by ATO 
in all cell lines (Fig. 5D).
In vivo effect of ATO on tumor xenografts. After inoculation of 
H226 cells for 7 days, obvious tumors were established. There 
was no significant difference in baseline tumor size amongst 
different groups of mice. The relative tumor size in the control 
and ATO treatment groups during treatment was determined 
(Fig. 6A). After 23 days of ATO treatment, the relative tumor 
volume in the 3.75 and 7.5 mg/kg treatment groups were 42.9 
and 46.5% that of the control group respectively (p<0.05). 
There was no difference in body weight between different 
groups (p>0.05) and no pathological changes (H&E staining) 
were observed in the liver of mice in the ATO treatment arms. 
E2F1 was suppressed and CC3 was upregulated in the ATO 
treatment arm (Fig. 6B), with IHC showing localization of 
CC3 to the nucleus (Fig. 6C).
Discussion
ATO showed antiproliferative effects as demonstrated by MTT 
cell viability assay with clinically achievable concentrations 
(18) in our cell line model accompanied by downregulation 
of TYMS (except H226 cells) and E2F1. The significance of 
TYMS in cell viability was demonstrated in vitro with TYMS 
knockdown, nonetheless with rather modest effect. In contrast, 
knockdown of the upstream target E2F1 resulted in more 
significant inhibition of cell viability. Our findings of down-
regulation of E2F1 and its various downstream signals would 
Figure 6. ATO treatment was associated with (A) stabilization of relative tumor size, (B) downregulation of E2F1 as well as upregulation of cleaved caspase-3 
expression and (C) localization of cleaved caspase-3 in the nucleus in the ATO treatment group compared with control group in H226 xenograft model. Results 
were measured in triplicate experiments. Statistical significance (*p<0.05, **p<0.01, ***p<0.001) indicates comparison with control.
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support E2F1 as a significant target of ATO leading to its anti-
proliferative effect. Upon treatment with ATO, apoptosis was 
also observed. In the H226 xenograft model, tumor growth 
was suppressed, E2F1 was downregulated while cleaved 
caspase-3 was upregulated and translocated to the nucleus in 
ATO treated mice.
It is evident that arsenic contamination in drinking water 
and food is related to liver, skin, kidney, bladder and lung 
cancers (19,20). Contrary to this though, ATO is being used 
for treatment of APL, mediated through SUMOylation of reti-
noic acid receptor α oncoprotein (21). ATO is also known to 
exert its anti-leukemic action through reactive oxygen species 
induction, mitochondrial membrane destruction, cytochrome c 
release, caspase activation and finally apoptosis (22-27). The 
US Food and Drug Administration has approved APL as an 
indication for treatment with ATO. Since TYMS is a key 
target in mesothelioma and ATO has recently been shown to 
suppress TYMS expression in lung adenocarcinoma (10) and 
colorectal cancer (11), we postulated that ATO would exert a 
TYMS inhibitory effect in mesothelioma cell lines.
In order to understand the significance of reduced 
protein expression of TYMS and TYMS activity by ATO 
in the 3 mesothelioma cell lines, the pivotal role of TYMS 
in cellular proliferation was studied using a TYMS knock-
down technique. However, the impact of TYMS knockdown 
on cell viability was unexpectedly low. The role of TYMS 
in mesothelioma is controversial which has been shown to 
be non-essential (6,7). Notably, the expression of E2F1 has 
demonstrated a strong correlation with cancer cell prolif-
eration (28,29), leading to our further exploration of a new 
actionable target the E2F1.
E2F1 is a well-known transcription factor which is involved 
in proliferation, apoptosis, cell cycle, tumor growth and senes-
cence. It is released and activated upon phosphorylation of 
retinoblastoma tumor suppressor protein (RB) (14). However, 
the role of E2F1 in mesothelioma has never been elucidated. 
Thus, E2F1-targeted siRNA experiment was performed to 
investigate the functional role of E2F1. Decrease in cell 
viability upon E2F1 knockdown was more profound when 
compared with TYMS, in support of a more important role 
of E2F1 than TYMS on cancer cell proliferation. Moreover, 
cleaved caspase-3 was elevated only in 211H cells (data not 
shown) after E2F1 knockdown showing that the relationship 
between E2F1 and apoptosis is cell line-specific. As such, the 
downstream targets of E2F1 related to cell proliferation and 
apoptosis were also investigated.
TYMS, TK and RRM1 are three key enzymes that take 
part in DNA synthesis and thus important in cell proliferation. 
TK activity in sarcomatoid type was reported to be higher 
than epithelioid type mesothelioma (30), which is in line with 
our observed relatively higher TK expression in sarcomatoid 
cells (H28 and H2052 cells). RRM1 polymorphisms and 
haplotypes were related to efficacy of gemcitabine treatment 
in mesothelioma (31). Interestingly, RRM1 downregulation 
by ATO was only observed in sarcomatoid mesothelioma cell 
lines in this study, suggesting a differential effect of ATO in 
different histological types of mesothelioma. Degradation of 
tumor suppressor proteins, e.g., p21 and p27, are induced by 
skp2 so as to accelerate cell cycle (32). Nonetheless, the role 
of skp2 in mesothelioma has so far not been described. Our 
findings have provided the first evidence of TK, RRM1 and 
skp2 downregulation by ATO in mesothelioma.
c-myc is a transcription factor which governs cell prolifera-
tion and metastasis. Suppression of c-myc has been shown to 
have antiproliferative (33) and apoptotic (34) effect in meso-
thelioma. In addition, growth inhibition in APL by ATO was 
partially mediated through suppression of c-myc (35).
JNK-c-JUN pathway regulates cell proliferation and 
upregulation of p-c-Jun mediates cell apoptosis (36). Apoptosis 
induced by ATO was reported only in one mesothelioma cell 
line (H2052) (12). Hence, we further studied the apoptotic 
effects of ATO in our 5 mesothelioma cell lines.
Phosphatidylserine (PS) externalization (37) and mitochon-
drial membrane depolarization (38) are well-known hallmarks of 
apoptosis. In addition, our findings of upregulated pro-apoptotic 
(Bak and cleaved caspase-3) and downregulated anti-apoptotic 
(Bcl-2 and Bcl-xL) proteins have provided supportive evidence 
that apoptosis was induced by ATO in mesothelioma cell lines.
The expression of cleaved caspase-3 in all mesothelioma cell 
lines increased in a dose-dependent manner with ATO, substan-
tiated in our H226 xenograft model. However, H28, 211H, H2052 
and H2452 xenograft models could not be generated despite 
multiple attempts. Based on IHC in H226 tumor xenografts, 
cytoplasmic cleaved caspase-3 was translocated to the nucleus, 
leading to subsequent chromatin condensation, DNA fragmen-
tation and/or nuclear disruption with eventual apoptosis (39). In 
addition, downregulation of E2F1 expression in H226 xenograft 
model with ATO treatment was observed. Our findings provide 
strong evidence for the in vitro and in vivo antiproliferative and 
pro-apoptotic effect of ATO in mesothelioma which is similar 
in lung adenocarcinoma recently reported (40).
In conclusion, ATO has demonstrated an antiproliferative 
effect at least partially mediated through downregulation of 
E2F1, as well as a cytotoxic effect through apoptosis in both 
in vitro and in vivo mesothelioma models. Moreover, we 
propose the E2F1 as a new actionable target in MPM. Our 
findings provide the scientific basis for future exploration of 
the clinical application of ATO in treatment of MPM. This is 
particularly feasible with the recent development of an oral-
ATO preparation by our institution for clinical use.
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